In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase

References

• Alhossary, A., Handoko, S. D., Mu, Y., & Kwoh, C. K. (2015). Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinformatics (Oxford, England), 31(13), 2214–2216. https://doi.org/10.1093/bioinformatics/btv082
   PubMed Web of Science ®Google Scholar
• Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2003). Mutational analysis of the tyrosine kinome in colorectal cancers. Science (New York, N.Y.), 300(5621), 949. https://doi.org/10.1126/science.1082596
   PubMed Web of Science ®Google Scholar
• Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. (2018). Kinase-targeted cancer therapies: Progress, challenges and future directions. Molecular Cancer, 17(1), 48. https://doi.org/10.1186/s12943-018-0804-2
   PubMedGoogle Scholar
• Blake, S., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008). The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology (Orlando, Fla.), 127(3), 330–339. https://doi.org/10.1016/j.clim.2008.02.006
   PubMed Web of Science ®Google Scholar
• Brümmendorf, T. H., Cortes, J. E., Souza, C. A., Guilhot, F., Duvillié, L., Pavlov, D., Gogat, K., Countouriotis, A. M., & Gambacorti‐Passerini, C. (2015). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial. British Journal of Haematology, 168(1), 69–81. https://doi.org/10.1111/bjh.13108
   PubMed Web of Science ®Google Scholar
• Case, D. A., Belfon, K., Ben-Shalom, I. Y., Brozell, S. R., Cerutti, D. S., Cheatham, T. E., III., & Kollman, P. A. (2020). AMBER 2020. University of California.
   Google Scholar
• Cortes, J. E., Kim, D. W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., & Gambacorti-Passerini, C. J. (2012). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. Journal of Clinical Oncology, 30(28), 3486–3492. https://doi.org/10.1200/JCO.2011.38.7522
   PubMed Web of Science ®Google Scholar
• Cortes, J., & Lang, F. (2021). Third-line therapy for chronic myeloid leukemia: Current status and future directions. Journal of Hematology & Oncology, 14(1), 44. https://doi.org/10.1186/s13045-021-01055-9
   PubMed Web of Science ®Google Scholar
• Cousins, K. R. (2011). Computer review of ChemDraw Ultra 12.0. Journal of the American Chemical Society, 133(21), 8388. https://doi.org/10.1021/ja204075s
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., … Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408–2417. https://doi.org/10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• Durrant, J. D., & McCammon, J. A. (2011a). BINANA: A novel algorithm for ligand-binding characterization. Journal of Molecular Graphics & Modelling, 29(6), 888–893. https://doi.org/10.1016/j.jmgm.2011.01.004
   PubMed Web of Science ®Google Scholar
• Durrant, J. D., & McCammon, J. A. (2011b). NNScore 2.0: A neural-network receptor-ligand scoring function. Journal of Chemical Information and Modeling, 51(11), 2897–2903. https://doi.org/10.1021/ci2003889
   PubMed Web of Science ®Google Scholar
• Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577–8593. https://doi.org/10.1063/1.470117
   Web of Science ®Google Scholar
• Ferguson, F., & Gray, N. (2018). Kinase inhibitors: The road ahead. Nature Reviews. Drug Discovery, 17(5), 353–377. https://doi.org/10.1038/nrd.2018.21
   PubMed Web of Science ®Google Scholar
• Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004). A census of human cancer genes. Nature Reviews. Cancer, 4(3), 177–183. −https://doi.org/10.1038/nrc1299
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Hazarika, M., White, R. M., Jr., Booth, B. P., Wang, Y. C., Ham, D. Y., Liang, C. Y., Rahman, A., Gobburu, J. V., Li, N., Sridhara, R., Morse, D. E., Lostritto, R., Garvey, P., Johnson, J. R., & Pazdur, R. (2005). Pemetrexed in malignant pleural mesothelioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11(3), 982–992. PMID: 15709163
   PubMed Web of Science ®Google Scholar
• Hazarika, M., White, R. M., Johnson, J. R., & Pazdur, R. (2004). FDA drug approval summaries: Pemetrexed (Alimta). The Oncologist, 9(5), 482–488. https://doi.org/10.1634/theoncologist.9-5-482
   PubMed Web of Science ®Google Scholar
• Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., Ortmann, C.-E., Menssen, H. D., Kantarjian, H., O'Brien, S. G., & Druker, B. J. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. The New England Journal of Medicine, 376(10), 917–927. https://doi.org/10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Høyvik, I.-M., Jansik, B., & Jørgensen, P. (2012). Trust region minimization of orbital localization functions. Journal of Chemical Theory and Computation, 8(9), 3137–3146. https://doi.org/10.1021/ct300473g
   PubMed Web of Science ®Google Scholar
• Huggins, D. J., Sherman, W., & Tidor, B. (2012). Rational approaches to improving selectivity in drug design. Journal of Medicinal Chemistry, 55(4), 1424–1444. https://doi.org/10.1021/jm2010332
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Kantarjian, H. M., Cortes, J. E., Kim, D. W., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E., Kelly, V., Turnbull, K., Besson, N., & Gambacorti-Passerini, C. (2014). Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 123(9), 1309–1318. https://doi.org/10.1182/blood-2013-07-513937
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, H., Nakamae, N. J., Gallagher, A., Hoenekopp, R. E., Blakesley, R. A., Larson, T. P., & Hughes, G. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology, 12(9), 841–851. https://doi.org/10.1016/S1470-2045(11)70201-7
   PubMed Web of Science ®Google Scholar
• Klamt, A. (2005). COSMO-RS: From quantum chemistry to fluid phase thermodynamics and drug design (1st ed.). Elsevier, 246 pages.
   Google Scholar
• Klamt, A., Moya, C., & Palomar, J. (2015). A comprehensive comparison of the IEFPCM and SS(V)PE continuum solvation methods with the COSMO approach. Journal of Chemical Theory and Computation, 11(9), 4220–4225. https://doi.org/10.1021/acs.jctc.5b00601
   PubMed Web of Science ®Google Scholar
• Klamt, A., & Schüürmann, G. (1993). COSMO: A new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. Journal of the Chemical Society, Perkin Transactions, 2, 799–805.
   Google Scholar
• Koroleva, E. V., Ignatovich, Z. I., Sinyutich, Y. V., & Gusak, K. N. (2016). Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. Russian Journal of Organic Chemistry, 52(2), 139–177. https://doi.org/10.1134/S1070428016020019
   Web of Science ®Google Scholar
• Köstler, W. J., & Zielinski, C. C. (2015). Targeting receptor tyrosine kinases in cancer. In Deric L. Wheeler and Yosef Yarden (Eds.), Receptor tyrosine kinases: Structure, functions and role in human disease (pp. 78–225). Spring.
   Google Scholar
• Kuseva, C., Schultz, T. W., Yordanova, D., Tankova, K., Kutsarova, S., Pavlov, T., Chapkanov, A., Georgiev, M., Gissi, A., Sobanski, T., & Mekenyan, O. G. (2019). The implementation of RAAF in the OECD QSAR Toolbox. Regulatory Toxicology and Pharmacology: RTP, 105, 51–61. https://doi.org/10.1016/j.yrtph.2019.03.018
   PubMed Web of Science ®Google Scholar
• Lehtola, S., & Jónsson, H. (2013). Unitary optimization of localized molecular orbitals. Journal of Chemical Theory and Computation, 9(12), 5365–5372. https://doi.org/10.1021/ct400793q
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26.
   PubMed Web of Science ®Google Scholar
• Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, S., Assouline, G., Etienne, F. E., Nicolini, P., le Coutre, R. E., Clark, L., Stenke, D., Andorsky, V., Oehler, S., Lustgarten, V. M., Rivera, T., Clackson, F. G., Haluska, M., Baccarani, J. E., Cortes, F., … Deininger, D. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial. The Lancet. Oncology, 17(5), 612–621. https://doi.org/10.1016/S1470-2045(16)00080-2
   PubMed Web of Science ®Google Scholar
• Liu, J., Zhang, Y., Huang, H., Lei, X., Tang, G., Cao, X., & Peng, J. (2021). Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. Chemical Biology & Drug Design, 97(3), 649–664. https://doi.org/10.1111/cbdd.13801
   PubMed Web of Science ®Google Scholar
• Maurer, G., Tarkowski, B., & Baccarini, M. (2011). Raf kinases in cancer-roles and therapeutic opportunities. Oncogene, 30(32), 3477–3488. −https://doi.org/10.1038/onc.2011.160
   PubMed Web of Science ®Google Scholar
• Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013). Shifting from the single to the multitarget paradigm in drug discovery. Drug Discovery Today, 18(9–10), 495–501. https://doi.org/10.1016/j.drudis.2013.01.008
   PubMed Web of Science ®Google Scholar
• Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004). Protein kinase inhibitors: Insights into drug design from structure. Science (New York, N.Y.), 303(5665), 1800–1805. https://doi.org/10.1126/science.1095920
   PubMed Web of Science ®Google Scholar
• O’Hare, T. (2016). A decade of nilotinib and dasatinib: From in vitro studies to first-line tyrosine kinase inhibitors. Cancer Research, 76(20), 5911–5913. https://doi.org/10.1158/0008-5472.CAN-16-2483
   PubMed Web of Science ®Google Scholar
• Patel, A. B., O'Hare, T., & Deininger, M. W. (2017). Mechanisms of resistance to ABL kinase inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematology/Oncology Clinics of North America, 31(4), 589–612. https://doi.org/10.1016/j.hoc.2017.04.007
   PubMed Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., Morris, J. H., & Ferrin, T. E. (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science: A Publication of the Protein Society, 30(1), 70–82. https://doi.org/10.1002/pro.3943
   PubMed Web of Science ®Google Scholar
• Proschak, E., Stark, H., & Merk, D. (2019). Polypharmacology by design: A medicinal chemist’s perspective on multitargeting compounds. Journal of Medicinal Chemistry, 62(2), 420–444.
   PubMed Web of Science ®Google Scholar
• Rappe, A. K., Casewit, C. J., Colwell, K. S., Goddard, W. A., III., & Skiff, W. M. (1992). UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. Journal of the American Chemical Society, 114(25), 10024–10035. https://doi.org/10.1021/ja00051a040
   Web of Science ®Google Scholar
• Roskoski, R. Jr., (2019). Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 144, 19–50. https://doi.org/10.1016/j.phrs.2019.03.006
   PubMed Web of Science ®Google Scholar
• Roskoski, R. Jr., (2021). Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological Research, 165, 105463. https://doi.org/10.1016/j.phrs.2021.105463
   PubMed Web of Science ®Google Scholar
• Ryckaert, J. P., Ciccotti, G., & Berendsen, H. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics, 23(3), 327–341. https://doi.org/10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Saglio, G., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R. A., & Kantarjian, H. M. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251–2259. https://doi.org/10.1056/NEJMoa0912614
   PubMed Web of Science ®Google Scholar
• Shen, C., Hu, Y., Wang, Z., Zhong, H., Zhang, H., Zhong, H., Wang, G., Yao, X., Xu, L., Cao, D., & Hou, T. (2021). Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions. Briefings in Bioinformatics, 22(1), 497–514. https://doi.org/10.1093/bib/bbz173
   PubMed Web of Science ®Google Scholar
• Stewart, J. (2013). Optimization of parameters for semiempirical methods VI: More modifications to the NDDO approximations and re-optimization of parameters. Journal of Molecular Modeling, 19(1), 1–32. https://doi.org/10.1007/s00894-012-1667-x
   PubMed Web of Science ®Google Scholar
• Stewart, J. (2016). MOPAC2016. Stewart computational chemistry. Google Scholar.
   Google Scholar
• Sun, H., Li, Y., Tian, S., Xu, L., & Hou, T. (2014). Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Physical Chemistry Chemical Physics: PCCP, 16(31), 16719–16729. https://doi.org/10.1039/c4cp01388c
   PubMed Web of Science ®Google Scholar
• Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019). Ponatinib: A novel multi-tyrosine kinase inhibitor against human malignancies. OncoTargets and Therapy, 12, 635–645. https://doi.org/10.2147/OTT.S189391
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Wang, D., Pan, H., & Wang, Y. (2017). T315L: A novel mutation within BCR-ABL kinase domain confers resistance against ponatinib. Leukemia & Lymphoma, 58(7), 1733–1735. https://doi.org/10.1080/10428194.2016.1251591
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general Amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Xu, L., Sun, H., Li, Y., Wang, J., & Hou, T. (2013). Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. The Journal of Physical Chemistry. B, 117(28), 8408–8421. https://doi.org/10.1021/jp404160y
   PubMed Web of Science ®Google Scholar
• Zhou, T., Commodore, L., Huang, W. S., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., Dalgarno, D. C., & Zhu, X. (2011). Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance. Chemical Biology & Drug Design, 77(1), 1–11. https://doi.org/10.1111/j.1747-0285.2010.01054.x
   PubMed Web of Science ®Google Scholar